Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Grows By 71.4%

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 174,800 shares, an increase of 71.4% from the February 29th total of 102,000 shares. Approximately 2.7% of the company’s stock are short sold. Based on an average trading volume of 619,400 shares, the days-to-cover ratio is presently 0.3 days.

TransCode Therapeutics Price Performance

TransCode Therapeutics stock remained flat at $0.68 during mid-day trading on Thursday. 248,159 shares of the company’s stock were exchanged, compared to its average volume of 664,147. The company has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $9.61. The firm has a market capitalization of $426,132.00, a P/E ratio of 0.00 and a beta of -0.38. TransCode Therapeutics has a twelve month low of $0.56 and a twelve month high of $392.00.

Institutional Investors Weigh In On TransCode Therapeutics

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in TransCode Therapeutics in the 4th quarter worth $46,000. UBS Group AG purchased a new position in shares of TransCode Therapeutics in the third quarter worth about $74,000. Sabby Management LLC lifted its holdings in shares of TransCode Therapeutics by 32.8% during the third quarter. Sabby Management LLC now owns 250,309 shares of the company’s stock worth $126,000 after purchasing an additional 61,872 shares during the period. Worth Venture Partners LLC boosted its position in TransCode Therapeutics by 9.7% in the first quarter. Worth Venture Partners LLC now owns 324,157 shares of the company’s stock valued at $934,000 after buying an additional 28,617 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in TransCode Therapeutics in the second quarter valued at approximately $25,000.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.